Literature DB >> 15465426

Consequences of NPC1 and NPC2 loss of function in mammalian neurons.

Steven U Walkley1, Kinuko Suzuki.   

Abstract

Genetic deficiency of NPC1 or NPC2 results in a devastating cholesterol-glycosphingolipidosis of brain and other organs known as Niemann-Pick type C (NPC) disease. While NPC1 is a transmembrane protein believed involved in retroendocytic shuttling of substrate(s) to the Golgi and possibly elsewhere in cells as part of an essential recycling/homeostatic control mechanism, NPC2 is a soluble lysosomal protein known to bind cholesterol. The precise role(s) of NPC1 and NPC2 in endosomal-lysosomal function remain unclear, nor is it known whether the two proteins directly interact as part of this function. The pathologic features of NPC disease, however, are well documented. Brain cells undergo massive intracellular accumulation of glycosphingolipids (lactosylceramide, glucosylceramide, GM2 and GM3 gangliosides) and cholesterol and concomitant distortion of neuron shape (meganeurite formation). In neurons from humans with NPC disease the metabolic defects and storage often lead to extensive growth of new, ectopic dendrites (possibly linked to ganglioside sequestration) as well as formation of neurofibrillary tangles (NFTs) (possibly linked to dysregulation of cholesterol metabolism). Other features of cellular pathology in NPC disease include fragmentation of the Golgi apparatus and neuroaxonal dystrophy, though reasons for these changes remain largely unknown. As the disease progresses, neurodegeneration is also apparent for neurons in some brain regions, particularly Purkinje cells of the cerebellum, but the basis of this selective neuronal vulnerability is unknown. The NPC1 protein is evolutionarily conserved with homologues reported in yeast to humans; NPC2 is reported in C. elegans to humans. While neurons in mammalian models of NPC1 and NPC2 diseases exhibit many changes that are remarkably similar to those in humans (e.g., endosomal/lysosomal storage, Golgi fragmentation, neuroaxonal dystrophy, neurodegeneration), a reduced degree of ectopic dendritogenesis and an absence of NFTs in these species suggest important differences in the way lower mammalian neurons respond to NPC1/NPC2 loss of function.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15465426     DOI: 10.1016/j.bbalip.2004.08.011

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  119 in total

1.  Knockdown of transmembrane protein 132A by RNA interference facilitates serum starvation-induced cell death in Neuro2a cells.

Authors:  Kentaro Oh-hashi; Kazuhide Imai; Hisashi Koga; Yoko Hirata; Kazutoshi Kiuchi
Journal:  Mol Cell Biochem       Date:  2010-05-09       Impact factor: 3.396

Review 2.  Pathophysiology of neuropathic lysosomal storage disorders.

Authors:  Cinzia Maria Bellettato; Maurizio Scarpa
Journal:  J Inherit Metab Dis       Date:  2010-04-29       Impact factor: 4.982

3.  Altered levels and distribution of amyloid precursor protein and its processing enzymes in Niemann-Pick type C1-deficient mouse brains.

Authors:  A Kodam; M Maulik; K Peake; A Amritraj; K S Vetrivel; G Thinakaran; J E Vance; S Kar
Journal:  Glia       Date:  2010-08-15       Impact factor: 7.452

Review 4.  Young-onset dementia.

Authors:  Dulanji K Kuruppu; Brandy R Matthews
Journal:  Semin Neurol       Date:  2013-11-14       Impact factor: 3.420

Review 5.  Beyond the cherry-red spot: Ocular manifestations of sphingolipid-mediated neurodegenerative and inflammatory disorders.

Authors:  Hui Chen; Annie Y Chan; Donald U Stone; Nawajes A Mandal
Journal:  Surv Ophthalmol       Date:  2013-09-05       Impact factor: 6.048

Review 6.  Mesenchymal stem cells as cellular vectors for pediatric neurological disorders.

Authors:  Donald G Phinney; Iryna A Isakova
Journal:  Brain Res       Date:  2014-05-22       Impact factor: 3.252

7.  Sphingolipid signalling mediates mitochondrial dysfunctions and reduced chronological lifespan in the yeast model of Niemann-Pick type C1.

Authors:  Rita Vilaça; Elísio Silva; André Nadais; Vítor Teixeira; Nabil Matmati; Joana Gaifem; Yusuf A Hannun; Maria Clara Sá Miranda; Vítor Costa
Journal:  Mol Microbiol       Date:  2013-12-12       Impact factor: 3.501

Review 8.  Treatment of Niemann--pick type C disease by histone deacetylase inhibitors.

Authors:  Paul Helquist; Frederick R Maxfield; Norbert L Wiech; Olaf Wiest
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

9.  Investigation of N-aryl-3-alkylidenepyrrolinones as potential Niemann-Pick type C disease therapeutics.

Authors:  Casey C Cosner; John T Markiewicz; Pauline Bourbon; Christopher J Mariani; Olaf Wiest; Madalina Rujoi; Anton I Rosenbaum; Amy Y Huang; Frederick R Maxfield; Paul Helquist
Journal:  J Med Chem       Date:  2009-10-22       Impact factor: 7.446

10.  MLN64 mediates egress of cholesterol from endosomes to mitochondria in the absence of functional Niemann-Pick Type C1 protein.

Authors:  Mark Charman; Barry E Kennedy; Nolan Osborne; Barbara Karten
Journal:  J Lipid Res       Date:  2009-10-29       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.